In the last trading session, 0.35 million shares of the Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) were traded, and its beta was 2.60. Most recently the company’s share price was $0.49, and it changed around -$0.02 or -4.99% from the last close, which brings the market valuation of the company to $124.15M. ADAP currently trades at a discount to its 52-week high of $2.05, offering almost -318.37% off that amount. The share price’s 52-week low was $0.51, which indicates that the current value has fallen by an impressive -4.08% since then.
Adaptimmune Therapeutics Plc ADR stock received a consensus recommendation rating of Buy, based on a mean score of 1.33. If we narrow it down even further, the data shows that 0 out of 9 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 2 recommended ADAP as a Hold, whereas 4 deemed it a Buy, and 1 rated it as Underweight. Adaptimmune Therapeutics Plc ADR is expected to report earnings per share of -0.15 for the current quarter.
Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) trade information
Instantly ADAP has showed a red trend with a performance of -4.99% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 0.6198 on recent trading dayincreased the stock’s daily price by 20.94%. The company’s shares are currently down -9.93% year-to-date, but still down -15.26% over the last five days. On the other hand, Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) is -17.76% down in the 30-day period.
The consensus price target as assigned by Wall Street analysts is $3, which translates to bulls needing to increase their stock price by 83.67% from its current value. Analyst projections state that ADAP is forecast to be at a low of $1 and a high of $4.
Adaptimmune Therapeutics Plc ADR (ADAP) estimates and forecasts
The year-over-year growth rate is expected to be 204.78%, up from the previous year.
Consensus estimates provided by 8 financial analysts predict the company will bring in an average of 9.01M in revenue for the current quarter. 3 analysts expect Adaptimmune Therapeutics Plc ADR to make 6.3M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 231k and 5.68M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 3,798.81%. Forecasts for the next quarter put sales growth at 10.95%. Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 10.30%.
Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP)’s Major holders
BANK OF AMERICA CORP /DE/, with 1.9239% or 4.65 million shares worth $4.53 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
SPDR Portfolio Developed World ex-US ETF and SEI Institutional International Tr-International Equity were the top two Mutual Funds as of Dec 31, 2024. The former held 251.08 shares worth $0.12 million, making up 0.10% of all outstanding shares. On the other hand, SEI Institutional International Tr-International Equity held roughly 175.24 shares worth around $82889.0, which represents about 0.07% of the total shares outstanding.
